Zai Lab receives Orphan Drug Designation from the U.S. FDA for ZL-1310 (DLL3 ADC) for...

YL201 received another Breakthrough Therapy Designation for the treatment of R/M Nasopharyngeal Carcinoma

Datroway (Datopotamab deruxtecan) approved in the US for patients with previously treated metastatic HR-positive, HER2-negative...

ArriVent BioPharma enters exclusive license with Lepu Biopharma for MRG007, an Antibody Drug Conjugate for...

Vincerx Pharma enters at-the-market equity offering deal

GI Innovation, LaNova Medicines sign MOU to develop combination therapy for pancreatic cancer